IDT Biologika GmbH is a biopharmaceutical contract development and manufacturing organization (CDMO) based in Germany. The company specializes in the development and GMP manufacturing of vaccines and viral vector–based biologics for human health, supporting programs from early clinical phases through commercial supply.
Its capabilities span process and analytical development, drug substance production in cell culture, aseptic fill–finish, lyophilization, packaging, quality control, and cold‑chain logistics. IDT Biologika operates to EU and US regulatory standards and serves pharmaceutical, biotechnology, and public health customers. With integrated development and manufacturing services, the company supports scalable bioprocessing for viral vaccines and gene therapy vectors, enabling accelerated and compliant delivery of complex biologics.
None yet. When a new project in the record names IDT Biologika GmbH as owner, partner or investor, it shows here.
The EU funds next-gen flu vaccines to enhance protection, speed up development, and improve pandemic readiness through pre-commercial procurement.
